BOA Acquisition Corp. II prices its $125 million SPAC IPO at $10 per unit, signaling renewed sponsor appetite for blank‑check vehicles amid a recovering M&A market
Executive summary: BOA Acquisition Corp. II announced the pricing of its initial public offering of 12.5 million units at $10.00 per share, generating $125 million in gross proceeds. The proceeds will sit in a trust account and can be used to fund a future business combination, providing the sponsor with substantial acquisition capacity in a market where SPAC activity is reviving.
Who is involved: BOA Acquisition Corp. II (sponsor), the underwriting syndicate (led by major investment banks), prospective investors, and the SEC as the overseeing regulator.
Likely next: The units are expected to begin trading on the NYSE under ticker ‘BOAU.U’ on August 5 2026; the SPAC has until August 2028 to complete a merger or return the trust proceeds to shareholders.
BOA Acquisition Corp. II, a special purpose acquisition company, priced its IPO at the full $10.00 per unit, raising $125 million that will be held in trust pending a future business combination. The pricing at the top of the indicated range reflects solid investor demand for SPACs after a quieter 2024‑25 period, suggesting sponsors are again confident in finding suitable targets. While the proceeds provide ample dry powder for a future de‑SPAC transaction, the vehicle will face the usual SEC scrutiny and a 24‑month deadline to complete a merger or return funds to investors.
Timeline
- — BOA Acquisition Corp. II Announces Pricing of $125 Million Initial Public Offering (PR Newswire)
Analysis — what this means
Likely next events
- BOA Acquisition Corp. II units expected to begin trading on the NYSE under ticker ‘BOAU.U’ on August 5 2026.
- BOA Acquisition Corp. II has 24 months from the IPO date (by August 2028) to complete a business combination or redeem the trust proceeds.
- Cartesian Growth Corp. II’s shareholder vote on the proposed $1.2 billion merger with InoBat AS is anticipated in Q1 2027.
- ADMA Biologics lead‑plaintiff motions must be filed by August 10 2026; if appointed, discovery would likely proceed in Q4 2026.
Sectors affected
- Special purpose acquisition companies (SPACs)
- Battery energy storage
- Biologics/biotech
- Legal services (M&A litigation)
Regulatory implications
- SEC Regulation S‑K and S‑X disclosure requirements for SPAC IPOs; potential new SPAC‑specific disclosure rules slated for early 2027.
- Possible SEC scrutiny under the Securities Exchange Act §10(b) and Rule 10b‑5 in the ADMA Biologics class‑action allegation.
Historical parallels
- 2021 SPAC boom exemplified by DraftKings’ merger with Diamond Eagle Acquisition Corp.
- SEC’s 2022 proposal to increase SPAC disclosure and sponsor promote limits.
- 2020 Nikola Corp. merger with VectoIQ Acquisition Corp., which later faced SEC inquiries and shareholder litigation.